Corvus Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV: $400M estimated peak sales for soquelitinib in relapsed/refractory PTCL, 30% probability of Phase 3 success and approval, 2.5x risk-adjusted peak-sales multiple, discounted 5 years to launch at 11%, plus $50M un-risked optionality for the atopic dermatitis Phase 2 program, plus $214.5M net cash; 92.4M basic shares outstanding.

Reasoning: Corvus is a pre-revenue clinical-stage biotech, so a standard revenue DCF isn't meaningful; value instead reflects net cash plus a probability-weighted NPV of its lead Phase 3 PTCL asset (orphan and Fast Track designated, positive Phase 1 data) and optionality on its earlier-stage atopic dermatitis program.